TCBP — TC BioPharm Cashflow Statement
0.000.00%
Last trade - 00:00- $2.63m
- $1.39m
Annual cashflow statement for TC BioPharm, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 10-K | 10-K |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.89 | -6.63 | -15 | -1.31 | -5.91 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.16 | 1.1 | 7.69 | -8.04 | -6.81 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.9 | 1.03 | 0.692 | -6.7 | 1.54 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -6.73 | -3.43 | -5.58 | -15.3 | -10.5 |
| Capital Expenditures | -2.2 | -0.205 | -0.143 | -0.365 | -0.209 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | 0.055 | 0 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -2.2 | -0.205 | -0.143 | -0.31 | -0.209 |
| Financing Cash Flow Items | 0.32 | -0.053 | -0.021 | 17.9 | 4.33 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.27 | 3.43 | 6.53 | 18.7 | 8.52 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -5.71 | -0.208 | 0.819 | 3.24 | -2.35 |